Status | Study |
Not yet recruiting |
Study Name: Pancreatic Neuroendocrine Tumor:Factor of Surgery Influencing Survival Condition: Pancreatic Neuroendocrine Tumor Date: 2015-11-30 Interventions: Procedure: pancreatectomy Remove the pancreatic neuroendocrine tumor by surgery |
Recruiting |
Study Name: Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Condition: Carcinoid Tumors Pancreatic NET Date: 2015-10-12 Interventions: Drug: Ibrutinib Ibrutinib will be administered orally once daily and each cycle will be defined as 4 wee |
Completed |
Study Name: An Analysis of Presentation and Outcome Following Treatment of Pancreatic Endocrine Neoplasms Condition: Pancreatic Endocrine Neoplasms Date: 2015-03-23 |
Recruiting |
Study Name: The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors Condition: Pancreatic Neuroendocrine Tumors Date: 2014-10-15 Interventions: Drug: sunitinib subjects will be enrolled to receive at least one dose of sunitinib orally at 37.5 mg on |
Recruiting |
Study Name: A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET) Condition: Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours Date: 2014-09-23 Interventions: Drug: lanreotide Patients will |
Recruiting |
Study Name: Observational Study In Real Life Settings Of The Systemic Treatment Of Well Differentiated, Unresectable Or Metastatic, Progressive Pancreatic Neuroendocrine Tumors (pNET): A Study Of Morbidity And Mortality At 2 Years Condition: Pancreatic Neuroendocrine Tumor, Well Differentiated and Progressive Date: 2014-09-02 Interventions: Drug: sunitinib sunitinib 37.5 |
Recruiting |
Study Name: A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus Condition: Pancreatic Neuroendocrine Tumour Metastatic Date: 2014-06-17 Interventions: Drug: Everolimus 10 mg daily everolimus is a recently approved mTOR inhibitor in advanced progressing we |
Completed |
Study Name: Comparative Study of Robotic, Laparoscopic and Open Surgery for Enucleation of Benign Pancreatic Neoplasms Condition: Pancreatic Neuroendocrine Tumors Date: 2014-04-26 Interventions: Procedure: Robotic surgery Rob |
Completed |
Study Name: Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor Condition: Advanced Well-differentiated Pancreatic Neuroendocrine Tumor Date: 2013-04-29 Interventions: Drug: temozolomide or dacarbazine-based chemotherapy, endostatin |
Completed |
Study Name: BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. Condition: Pancreatic Neuroendocrine Tumors (pNET) Date: 2012-07-06 Interventions: Drug: BEZ235 (Stage 1) The investigational study drug used in this trial was BEZ235, which was supplied |